Close Menu

NEW YORK — Novacyt reported on Thursday a four percent drop in revenues for 2019, alongside a 40 percent jump in its total net loss for the year. The French diagnostics firm downplayed the impact of the results, however, citing surging demand for its SARS-CoV-2 test.

That qPCR-based test was launched in late January and sales, orders, and commitments for its purchase have "significantly exceeded expectations," Novacyt said. As a result, 2019's financial results "do not have a material bearing on the current business."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.